Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours 1

319 - Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC


20 Dec 2015


Gastrointestinal tumours 1


Ming-ming He


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


R. Xu1, Y. Li1, H. Luo1, W. Wang2, Z. Wang1, X. Yuan3, D. Ma4, F.H. Wang1, D. Zhang1, D.R. Lin5, J. Jia6, X.H. Hu7, J.W. Peng8, Y.C. Lin9

Author affiliations

  • 1 Medical Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 2 Medical Oncology, Foshan No.1 People's Hospital, Foshan/CN
  • 3 Medical Oncology, Huizhou Central Hospital, Huizhou/CN
  • 4 Medical Oncology, Guangdong General Hospital, Guangzhou/CN
  • 5 Medical Oncology, Jiangmen Central Hospital, jiangmen/CN
  • 6 Medical Oncology, Dongguan People's Hospital, Dongguan/CN
  • 7 Medical Oncology, Cancer Hospital of Guangxi Medical University, Nanning/CN
  • 8 Medical Oncology, Zhongshan People's Hospital, zhongshan/CN
  • 9 Medical Oncology, Cancer Hospital of Shantou University, Shantou/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 319


Our previous non-randomized study indicated that patients receiving first-line treatment of XELOX followed by capecitabine as maintaining therapy had significantly prolonged median time to progression. Therefore, we initiated this randomized study to evaluate the efficacy and safety of maintenance therapy with capecitabine after induction of XELOX (or FOLFOX) in first-line treatment of mCRC.


In this multi-center, randomized phase III study, patients were received 18-24 weeks of XELOX or FOLFOX. Following the chemotherapy, patients who achieved controlled disease (CR, PR or SD) were randomized 1:1 to receive maintenance therapy of capecitabine (1,000 mg/m2 twice a day from days 1–14, every 3 weeks) or only observation until disease progression. The primary endpoint was PFS; the secondary endpoint was overall survival (OS).


The intent-to-treat population comprised of 274 patients (capecitabine maintenance, n= 136; observation, n = 138). There were no significant differences in baseline characteristics between capecitabine maintenance group and observation group. The median follow-up was 29.0 months (range, 0–62.5 months). Median PFS in capecitabine maintenance group was significantly longer than observation group (10.43 [95% confidence interval (CI) 9.70 to 12.23] vs. 7.82 [95% CI 7.00 to 8.60] months; p < 0.0001). The secondary endpoint of median OS in capecitabine maintenance group was longer than observation group, but not statistically significant (23.17 vs. 19.73 months; p = 0.2548). There was no significant difference between XELOX or FOLFOX and the relevant observation group with respect to OS. Similar safety profiles were observed in both arms. The most common grade 3 or 4 toxicities in capecitabine maintenance versus observation were neutropenia, hand–foot syndrome, and mucositis.


Maintenance therapy with single agent capecitabine after induction of XELOX or FOLFOX seems beneficial in mCRC, demonstrating a prolonged PFS with acceptable toxicities.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings